{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-17T13:58:25.889237+00:00","company":{"ticker":"ALMR","cik":2104204,"company_name":"Alamar Biosciences, Inc."},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{},"facts":[{"fact_type":"earnings_release","fact_key":"9797b1efa79dccf3f62cce2978ec35795e780250","cik":2104204,"ticker":"ALMR","company_name":"Alamar Biosciences, Inc.","filed_at":"2026-05-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$21.3 million","period_text":"the quarter ended March 31, 2026","report_date":"2026-05-08","result_type":"reported_results","revenue_text":"$26.0 million"},"claim":"Alamar Biosciences, Inc. reported the quarter ended March 31, 2026 results: revenue $26.0 million, net income $21.3 million.","evidence_excerpt":"Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026. Recent Highlights • Generated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025. • Launched two new products, NULISAseqTM Neuro 220 Panel and","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-213379","anchor_url":"https://secwatch.observer/filing/0001193125-26-213379#claim-9797b1efa79dccf3f62cce2978ec35795e780250","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2104204/000119312526213379/0001193125-26-213379-index.htm"},{"fact_type":"governance_change","fact_key":"47485fbbd56a7f54c9a7d52bffddfd8ae2466c60","cik":2104204,"ticker":"ALMR","company_name":"Alamar Biosciences, Inc.","filed_at":"2026-04-20T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2026-04-20","item_codes_triggered":["5.03"],"summary_text":"Adopted amended and restated bylaws effective April 20, 2026."},"claim":"Alamar Biosciences, Inc.: Adopted amended and restated bylaws effective April 20, 2026 (effective 2026-04-20).","evidence_excerpt":"Effective as of April 20, 2026, the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-163921","anchor_url":"https://secwatch.observer/filing/0001193125-26-163921#claim-47485fbbd56a7f54c9a7d52bffddfd8ae2466c60","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2104204/000119312526163921/0001193125-26-163921-index.htm"},{"fact_type":"governance_change","fact_key":"491091ecd3bc339e089acaf93c0dbf326465a6ff","cik":2104204,"ticker":"ALMR","company_name":"Alamar Biosciences, Inc.","filed_at":"2026-04-20T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-04-20","item_codes_triggered":["5.03"],"summary_text":"Filed amended and restated certificate of incorporation effective as of immediately prior to the closing of the IPO on April 20, 2026."},"claim":"Alamar Biosciences, Inc.: Filed amended and restated certificate of incorporation effective as of immediately prior to the closing of the IPO on April 20, 2026 (effective 2026-04-20).","evidence_excerpt":"the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware. The Company’s board of directors (the “Board”) and stockholders previously approved the Restated Certificate to be effective as of immediately prior to the closing of the IPO.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-163921","anchor_url":"https://secwatch.observer/filing/0001193125-26-163921#claim-491091ecd3bc339e089acaf93c0dbf326465a6ff","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2104204/000119312526163921/0001193125-26-163921-index.htm"}]}